Industries

Pharmaceuticals

From CMC through commercial supply, pharma runs on validated systems: SAP, LIMS, MES, SCADA, eQMS, RIM. Cybroscape gives you a CSA-native validation practice, TraceDraft for clinical documentation, and GxP Copilot for continuous validation across the estate.

Quick chat on WhatsAppHuman review at every gatePart 11 readyISO 9001 & 27001 certified

FDAEMAMHRAPMDACDSCOGAMP 5ICH Q921 CFR Part 11

In short

Validation in pharmaceutical manufacturing answers to GMP, with EU GMP Annex 11 for computerised systems and Annex 15 for equipment qualification. The systems that carry the most risk are the ones closest to the batch record — MES, SCADA, LIMS and the ERP modules that touch batch and quality data — because a failure there reaches product quality directly.

Roadblocks

Identify The Roadblocks Slowing Your Growth

These challenges compound: cycles slow, scaling gets harder, and inspection posture drifts.

01Legacy validation practice bloats test effort

02Legacy paper-heavy documentation slows submissions

03Fragmented traceability across CMC, quality and clinical

04AI adoption stalled by unclear Annex 22 posture

Regulations

Regulations We Cover

Every pharma engagement is mapped to the regulations your inspectors will use.

Pharma
GMP

FDA 21 CFR Part 210/211/11
EU GMP Annex 11 / Annex 22
ICH Q7 / Q9 / Q10
GAMP 5 Second Edition

Where validation sits

01DevelopmentELNLIMSCDSDevelopment data that is complete and attributable
02ManufacturingMESSCADAERPBatch records and process control
03Quality controlLIMSCDSInstrumentsTest results and their audit trails
04Batch releaseeQMSERPRelease on reviewed, signed evidence
05DistributionWMSTemperature monitoringStorage and transport conditions
06Post-marketSafety databaseRIMComplaints, safety cases and variations

Where validated systems sit across a typical pharma value chain, and what an inspector looks at in each stage. Typical systems shown; your estate will differ.

For pharma

Services & Products For Pharmaceuticals

Services

Products

Case study · Pharmaceuticals

SAP S/4HANA validation for a mid-market oral-solid-dose manufacturer

A CSA-native validation of SAP S/4HANA batch management, QM and materials — delivered against a fixed 12-week inspection window, with a defensible reduction in scripted-test effort and a live traceability view standing at go-live.

Read the case study

12 wkTo inspection-ready

Risk-ledTest depth set per requirement, with rationale

3Sites harmonised

CleanMock inspection, no material findings

Validation Complexity in Large-Scale GMP Manufacturing

Pharmaceutical manufacturers operating under 21 CFR Part 210/211 and EU GMP face a validation estate that has grown faster than the teams managing it. A single mid-sized site may carry hundreds of validated systems — SAP ERP, MES, SCADA, LIMS, and eQMS platforms — each with its own IQ/OQ/PQ documentation trail, change control history, and periodic review obligation. The gap between what regulators expect under EU GMP Annex 11 and what most validation teams can sustain is widening every cycle.

Cybroscape's validation consulting practice works directly inside these estates. We inherit your existing CSV documentation, rationalise qualification backlogs against ICH Q9 risk principles, and build forward-looking validation strategies that survive audits — not just inspections. Our LIMS and MES validation work spans Oracle, SAP, LabWare, and Körber platforms, giving us pattern recognition that internal teams rarely accumulate at a single site.

Legacy System Modernisation and the Annex 11 Reckoning

Legacy validated systems — many originally qualified in the early 2000s — now face a reckoning. EU GMP Annex 11's expectations around audit trails, data integrity, access controls, and backup/recovery are not negotiable, but many inherited systems predate those requirements being enforced. Re-validating a SCADA historian or a 15-year-old LIMS against modern ALCOA+ principles is not a documentation exercise; it requires genuine technical understanding of the system's data architecture and data flow.

Our legacy modernisation engagements begin with a gap assessment benchmarked against current MHRA, EMA, and FDA data integrity guidance. We identify which deficiencies require remediation, which can be mitigated through procedural controls, and which systems should be retired. Where replacement is the right call, we manage the parallel validation of the incoming platform without disrupting ongoing GMP operations or triggering a product impact assessment mid-campaign.

Running a validated estate?Talk to a pharma lead, or chat with us on WhatsApp.

ICH Q9(R1) and Q10: Risk-Based Qualification Across the Site

ICH Q9(R1) formalised the expectation that validation depth should be proportionate to risk — yet many pharma sites still apply uniform IQ/OQ/PQ protocols regardless of system criticality. The result is over-documentation of low-risk administrative tools and under-qualification of direct-impact manufacturing systems. Our practice re-calibrates validation programmes against a defensible risk framework, scoring systems on GMP impact, data criticality, and regulatory exposure before a single protocol is written.

Under ICH Q10, the pharmaceutical quality system must drive continuous improvement — not just compliance maintenance. We help quality teams build validation life cycle management into their QMS so that change control, periodic reviews, and revalidation triggers are systematic rather than reactive. This directly reduces the audit finding rate for data integrity and CSV-related 483 observations, which remain among the most frequently cited categories in FDA warning letters.

AI Adoption in GMP Manufacturing Under EU GMP Annex 22

Draft EU GMP Annex 22 on Artificial Intelligence signals that regulators will hold AI systems in GMP environments to the same rigorous qualification standards as any other computerised system. Pharma organisations piloting AI for process analytical technology, batch release prediction, or anomaly detection need validation strategies that address model governance, training data integrity, concept drift monitoring, and explainability before they appear on an agency's radar.

GxP Copilot, Cybroscape's AI-native validation platform, provides the compliance scaffolding that responsible AI adoption requires. It tracks the full validation life cycle for AI/ML models deployed in GMP contexts — from URS and risk assessment through qualification testing and ongoing performance monitoring — generating the audit-ready evidence package that Annex 22 will mandate. Pharma teams can accelerate AI adoption without outrunning their compliance posture.

1Bounded intended useWhat the model does, and what it must not be used for

2A frozen evaluation setHeld-out data, version-controlled, agreed before testing

3A release gate that holdsAcceptance criteria set in advance, results recorded

4A person decides what mattersConsequential calls are made and signed by a named person

5Drift monitoring in productionInputs, outputs and overrides watched, with authority to suspend

6A fallback that actually runsThe process continues with the AI switched off

Annex 22 · consultation draft

The six parts of validating an AI system for GxP use. They map onto what the EU’s draft Annex 22 asks for. Annex 22 is still a consultation draft, not yet in force.

CSR and Submission Workload: Where Documentation Breaks Down

For pharma companies managing late-stage pipelines, the bottleneck is rarely the science — it is the documentation. Clinical Study Reports, ICH M4 CTD modules, risk management documentation under ICH Q9, and RIM platform content all compete for the same finite pool of qualified medical writers and regulatory affairs specialists. Submission timelines slip not because of data gaps but because structured drafting capacity runs out at precisely the wrong moment.

TraceDraft, our AI-native regulatory document generation platform, addresses this directly. Built for validated submission environments, TraceDraft maintains source traceability from protocol to CSR to submission module, generates structured first drafts aligned to ICH and FDA templates, and embeds a review workflow that quality teams can audit. It removes the hours regulatory writers spend on mechanical structuring so they can focus on clinical interpretation and agency response.

Building a Sustainable Validation Operating Model

Reactive validation — qualifying systems only when an inspection or project forces it — is a structural risk. Pharma sites that lack a documented Validation Master Plan aligned to their system inventory, change control cadence, and periodic review schedule will eventually face a 483 observation that traces back to a gap that was always visible but never prioritised.

Cybroscape helps pharmaceutical clients build proactive validation operating models: a live, risk-stratified system inventory, a rolling qualification schedule tied to the change control board, and GxP Copilot automating the documentation workflow so validation managers spend their time on technical decisions rather than template population. The output is a quality system that satisfies inspectors and actually works for the teams running it.